Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новости Международного гепатологического конгресса EASL 2018
Новости Международного гепатологического конгресса EASL 2018
Вялов С.С. Новости Международного гепатологического конгресса EASL 2018. Справочник поликлинического врача. 2018; 5: 50–53.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Европейское общество по изучению печени ежегодно проводит Международный печеночный конгресс, или, как его еще называют, Европейскую неделю гепатологии. В этом году мероприятие проводилось весной в Париже. На конференции было представлено огромное количество устных и постерных докладов, наиболее важные результаты исследования приведены в нашем обзоре.
Ключевые слова: алкогольная болезнь печени, вирусный гепатит С.
Key words: alcoholic liver disease, viral hepatitis С.
Ключевые слова: алкогольная болезнь печени, вирусный гепатит С.
________________________________________________
Key words: alcoholic liver disease, viral hepatitis С.
Полный текст
Список литературы
1. Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2017; DOI: 10.1016/j.cgh.2017.11.045
2. Goldberg D et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152 (5): 1090–9.e1.
3. Flemming JA et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65 (3): 804–12.
4. Grant BF et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74 (9): 911–23.
5. Bajaj JS et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018. DOI: 10.1002/hep.29791
6. Bajaj JS et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5): 940–7.
7. Qin N et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513 (7516): 59–64.
8. European Centre for Disease Prevention and Control. Hepatitis E in the EU/EEA, 2005–2015. Baseline assessment of testing, diagnosis, surveillance and epidemiology. https://ecdc.europa.eu/en/publications-data/hepatitis-e-eueea-2005-2015.
9. Van der Poel WHM et al. Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. Transbound Emerg Dis 2018. DOI: 10.1111/tbed.12760
10. World Health Organization. Hepatitis E Factsheet. http://www.who.int/mediacentre/factsheets/fs280/en/
11. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012; 86 (11): 1027–34.
12. Stene-Johansen K et al. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 2007; 79 (4): 356–65.
13. Bruni R et al. Hepatitis A virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014. BMC Infect Dis 2017; 17 (1): 497.
14. Stuurman AL et al. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Hum Vaccin Immunother 2017; 13 (3): 724–36.
15. Dhiman RK. Future of therapy for hepatitis c in India: a matter of accessibility and affordability? J Clin Exp Hepatol 2014; 4 (2): 85–6.
16. Puri P et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol 2014; 4 (2): 106–16.
17. Dhiman RK et al. Tackling the hepatitis C disease burden in Punjab, India. J Clin Exp Hepatol 2016; 6 (3): 224–32.
18. Jindal N et al. Risk factors and genotypes of HCV infected patients attending tertiary care hospital in North India. Indian J Med Microbiol 2015; 33 (1): 189–90.
19. Jalan R et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (6): 1310–24.
20. Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol 2015; 7 (7): 916–21.
21. Salerno F et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int 2017; 37 (1): 71–9.
22. Schierwagen R et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 312 (5): G407–12.
23. Vargas JI et al. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
24. Abraldes JG, Burak KW. STAT order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology 2016; 64 (1): 13–5.
25. Kuver R. The effects of statins on cholestasis: good, bad or indifferent? J Gastroenterol Hepatol 2011; 26 (10): 1467–9.
26. Zeuzem S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–69.
27. Gane E et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377 (15): 1448–55.
28. Forns X et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–8.
29. Asselah T et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (3): 417–26.
30. Kwo PY et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017; 67 (2): 263–71.
2. Goldberg D et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152 (5): 1090–9.e1.
3. Flemming JA et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65 (3): 804–12.
4. Grant BF et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74 (9): 911–23.
5. Bajaj JS et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018. DOI: 10.1002/hep.29791
6. Bajaj JS et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5): 940–7.
7. Qin N et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513 (7516): 59–64.
8. European Centre for Disease Prevention and Control. Hepatitis E in the EU/EEA, 2005–2015. Baseline assessment of testing, diagnosis, surveillance and epidemiology. https://ecdc.europa.eu/en/publications-data/hepatitis-e-eueea-2005-2015.
9. Van der Poel WHM et al. Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. Transbound Emerg Dis 2018. DOI: 10.1111/tbed.12760
10. World Health Organization. Hepatitis E Factsheet. http://www.who.int/mediacentre/factsheets/fs280/en/
11. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012; 86 (11): 1027–34.
12. Stene-Johansen K et al. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 2007; 79 (4): 356–65.
13. Bruni R et al. Hepatitis A virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014. BMC Infect Dis 2017; 17 (1): 497.
14. Stuurman AL et al. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Hum Vaccin Immunother 2017; 13 (3): 724–36.
15. Dhiman RK. Future of therapy for hepatitis c in India: a matter of accessibility and affordability? J Clin Exp Hepatol 2014; 4 (2): 85–6.
16. Puri P et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol 2014; 4 (2): 106–16.
17. Dhiman RK et al. Tackling the hepatitis C disease burden in Punjab, India. J Clin Exp Hepatol 2016; 6 (3): 224–32.
18. Jindal N et al. Risk factors and genotypes of HCV infected patients attending tertiary care hospital in North India. Indian J Med Microbiol 2015; 33 (1): 189–90.
19. Jalan R et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (6): 1310–24.
20. Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol 2015; 7 (7): 916–21.
21. Salerno F et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int 2017; 37 (1): 71–9.
22. Schierwagen R et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 312 (5): G407–12.
23. Vargas JI et al. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
24. Abraldes JG, Burak KW. STAT order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology 2016; 64 (1): 13–5.
25. Kuver R. The effects of statins on cholestasis: good, bad or indifferent? J Gastroenterol Hepatol 2011; 26 (10): 1467–9.
26. Zeuzem S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–69.
27. Gane E et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377 (15): 1448–55.
28. Forns X et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–8.
29. Asselah T et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (3): 417–26.
30. Kwo PY et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017; 67 (2): 263–71.
2. Goldberg D et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152 (5): 1090–9.e1.
3. Flemming JA et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65 (3): 804–12.
4. Grant BF et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74 (9): 911–23.
5. Bajaj JS et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018. DOI: 10.1002/hep.29791
6. Bajaj JS et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5): 940–7.
7. Qin N et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513 (7516): 59–64.
8. European Centre for Disease Prevention and Control. Hepatitis E in the EU/EEA, 2005–2015. Baseline assessment of testing, diagnosis, surveillance and epidemiology. https://ecdc.europa.eu/en/publications-data/hepatitis-e-eueea-2005-2015.
9. Van der Poel WHM et al. Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. Transbound Emerg Dis 2018. DOI: 10.1111/tbed.12760
10. World Health Organization. Hepatitis E Factsheet. http://www.who.int/mediacentre/factsheets/fs280/en/
11. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012; 86 (11): 1027–34.
12. Stene-Johansen K et al. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 2007; 79 (4): 356–65.
13. Bruni R et al. Hepatitis A virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014. BMC Infect Dis 2017; 17 (1): 497.
14. Stuurman AL et al. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Hum Vaccin Immunother 2017; 13 (3): 724–36.
15. Dhiman RK. Future of therapy for hepatitis c in India: a matter of accessibility and affordability? J Clin Exp Hepatol 2014; 4 (2): 85–6.
16. Puri P et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol 2014; 4 (2): 106–16.
17. Dhiman RK et al. Tackling the hepatitis C disease burden in Punjab, India. J Clin Exp Hepatol 2016; 6 (3): 224–32.
18. Jindal N et al. Risk factors and genotypes of HCV infected patients attending tertiary care hospital in North India. Indian J Med Microbiol 2015; 33 (1): 189–90.
19. Jalan R et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (6): 1310–24.
20. Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol 2015; 7 (7): 916–21.
21. Salerno F et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int 2017; 37 (1): 71–9.
22. Schierwagen R et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 312 (5): G407–12.
23. Vargas JI et al. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
24. Abraldes JG, Burak KW. STAT order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology 2016; 64 (1): 13–5.
25. Kuver R. The effects of statins on cholestasis: good, bad or indifferent? J Gastroenterol Hepatol 2011; 26 (10): 1467–9.
26. Zeuzem S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–69.
27. Gane E et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377 (15): 1448–55.
28. Forns X et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–8.
29. Asselah T et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (3): 417–26.
30. Kwo PY et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017; 67 (2): 263–71.
________________________________________________
2. Goldberg D et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152 (5): 1090–9.e1.
3. Flemming JA et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65 (3): 804–12.
4. Grant BF et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74 (9): 911–23.
5. Bajaj JS et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018. DOI: 10.1002/hep.29791
6. Bajaj JS et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5): 940–7.
7. Qin N et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513 (7516): 59–64.
8. European Centre for Disease Prevention and Control. Hepatitis E in the EU/EEA, 2005–2015. Baseline assessment of testing, diagnosis, surveillance and epidemiology. https://ecdc.europa.eu/en/publications-data/hepatitis-e-eueea-2005-2015.
9. Van der Poel WHM et al. Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. Transbound Emerg Dis 2018. DOI: 10.1111/tbed.12760
10. World Health Organization. Hepatitis E Factsheet. http://www.who.int/mediacentre/factsheets/fs280/en/
11. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012; 86 (11): 1027–34.
12. Stene-Johansen K et al. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 2007; 79 (4): 356–65.
13. Bruni R et al. Hepatitis A virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014. BMC Infect Dis 2017; 17 (1): 497.
14. Stuurman AL et al. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Hum Vaccin Immunother 2017; 13 (3): 724–36.
15. Dhiman RK. Future of therapy for hepatitis c in India: a matter of accessibility and affordability? J Clin Exp Hepatol 2014; 4 (2): 85–6.
16. Puri P et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol 2014; 4 (2): 106–16.
17. Dhiman RK et al. Tackling the hepatitis C disease burden in Punjab, India. J Clin Exp Hepatol 2016; 6 (3): 224–32.
18. Jindal N et al. Risk factors and genotypes of HCV infected patients attending tertiary care hospital in North India. Indian J Med Microbiol 2015; 33 (1): 189–90.
19. Jalan R et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (6): 1310–24.
20. Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol 2015; 7 (7): 916–21.
21. Salerno F et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int 2017; 37 (1): 71–9.
22. Schierwagen R et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 312 (5): G407–12.
23. Vargas JI et al. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
24. Abraldes JG, Burak KW. STAT order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology 2016; 64 (1): 13–5.
25. Kuver R. The effects of statins on cholestasis: good, bad or indifferent? J Gastroenterol Hepatol 2011; 26 (10): 1467–9.
26. Zeuzem S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–69.
27. Gane E et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377 (15): 1448–55.
28. Forns X et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–8.
29. Asselah T et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (3): 417–26.
30. Kwo PY et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017; 67 (2): 263–71.
Авторы
С.С.Вялов
ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 8, корп. 1;
ФГБОУ ВО «Московский государственный технический университет им. Н.Э.Баумана (Национальный исследовательский университет)». 105005, Россия, Москва, ул. 2-я Бауманская, д. 5, стр. 1;
Global Medical System clinic & hospitals, French clinic. 121099, Россия, Москва, 1-й Николощеповский пер., д. 6, стр. 1
svialov@mail.ru
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 8, korp. 1;
N.E.Bauman Moscow State Technical University. 105005, Russian Federation, Moscow, ul. 2-ia Baumanskaia, d. 5, str. 1;
GMS clinic & hospitals, French clinic. 121099, Russian Federation, Moscow, 1-i Nikoloshepovskii per., d. 6, str. 1
svialov@mail.ru
ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 8, корп. 1;
ФГБОУ ВО «Московский государственный технический университет им. Н.Э.Баумана (Национальный исследовательский университет)». 105005, Россия, Москва, ул. 2-я Бауманская, д. 5, стр. 1;
Global Medical System clinic & hospitals, French clinic. 121099, Россия, Москва, 1-й Николощеповский пер., д. 6, стр. 1
svialov@mail.ru
________________________________________________
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 8, korp. 1;
N.E.Bauman Moscow State Technical University. 105005, Russian Federation, Moscow, ul. 2-ia Baumanskaia, d. 5, str. 1;
GMS clinic & hospitals, French clinic. 121099, Russian Federation, Moscow, 1-i Nikoloshepovskii per., d. 6, str. 1
svialov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.